Progression in ALS is not linear but is curvilinear

Journal of Neurology

Volumn 257, Issue 10, 2010, Pages 1713-1717

  Gordon, Paul H ^a   Cheng, Bin ^b   Salachas, Francois ^a   Pradat, Pierre Francois ^a   Bruneteau, Gaelle ^a   Corcia, Philippe ^a,c   Lacomblez, Lucette ^a   Meininger, Vincent ^a  

^a PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^b Och Spine at New York Presbyterian Hospitals   (United States)

^c ALS Center   (France)

Author keywords

Amyotrophic lateral sclerosis; Clinical trials; Natural history; Rate of progression; Survival

Indexed keywords

ADULT; AGE DISTRIBUTION; AMYOTROPHIC LATERAL SCLEROSIS; ARTICLE; CLINICAL FEATURE; DEMOGRAPHY; DETERIORATION; DISEASE COURSE; FEMALE; FOLLOW UP; FUNCTIONAL STATUS; HUMAN; MAJOR CLINICAL STUDY; MALE; PREDICTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; RATING SCALE; SURVIVAL; AGED; MIDDLE AGED; MORTALITY; NONLINEAR SYSTEM; PATHOPHYSIOLOGY; PREDICTIVE VALUE; PROPORTIONAL HAZARDS MODEL; RETROSPECTIVE STUDY; TIME;

ADULT; AGED; AMYOTROPHIC LATERAL SCLEROSIS; DISEASE PROGRESSION; FEMALE; HUMANS; MALE; MIDDLE AGED; NONLINEAR DYNAMICS; PREDICTIVE VALUE OF TESTS; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS; TIME FACTORS;

EID: 79952199408     PISSN: 03405354     EISSN: 14321459     Source Type: Journal    
DOI: 10.1007/s00415-010-5609-1     Document Type: Article

References (27)

1. Rowland LP, Shneider NA (2001) Amyotrophic lateral sclerosis. N Engl J Med 344:1688-1700
2. Meininger V, Binsimon G, Lacomblez L, Salachas F (1995) Natural history of amyotrophic lateral sclerosis: a discussion. Adv Neurol 68:199-207
3. Guiloff RJ, Goonetilleke A (1995) Natural history of amyotrophic lateral sclerosis: observations with the charing cross amyotrophic lateral sclerosis rating scales. Adv Neurol 68:185-198
4. Pradas J, Finison L, Andres PL, Thornell B, Hollander D, Munsat TL (1993) The natural history of amyotrophic lateral sclerosis and the use of natural history controls in therapeutic trials. Neurology 43:751-755
5. Moore DH, Miller RG (2004) Improving efficiency of ALS clinical trials using lead-in designs. Amyotroph Lateral Scler Other Motor Neuron Disord 5:57-60
6. Gordon PH, Moore DH, Miller RG et al (2007) Minocycline is not effective for amyotrophic lateral sclerosis: a phase III randomized controlled trial. Lancet Neurol 6:1045-1053
7. Miller RG, Moore DH (2004) ALS trial design: expectation and reality. Amyotroph Lateral Scler Other Motor neuron Disord 5:52-54
8. Gordon PH, Corcia P, Lacomblez L et al (2009) Defining survival as an outcome measure in amyotrophic lateral sclerosis. Arch Neurol 66:758-761
9. Cedarbaum JM, Stambler N, Malta E et al (1999) The ALSFRS-R: a revised ALS functional rating scale that incorporates assessments of respiratory function. BDNF ALS Study Group (Phase II/III). J Neurol Sci 169:13-21
10. ALS Great Lakes Study Group (2003) A comparison of muscle strength testing techniques in amyotrophic lateral sclerosis. Neurology 61:1503-1507
11. Brooks BR, Miller RG, Swash M, Munsat TL (2000) World Federation of Neurology Research Group on Motor Neuron Diseases. El Escorial revisited: revised criteria for the diagnosis of amyotrophic lateral sclerosis. Amyotroph Lateral Scler Other Motor Neuron Disord 1:293-299
12. A double-blind placebo-controlled clinical trial of subcutaneous recombinant human ciliary neurotrophic factor (rHCNTF) in amyotrophic lateral sclerosis (1996) ALS CNTF Treatment Study Group. Neurology 46:1244-1249
13. Meininger V, Drory VE, Leigh PN, Ludolph A, Robberecht W, Silani V (2009) Glatiramer acetate has no impact on disease progression in ALS at 40 mg/day: a double-blind, randomized, multicentre, placebo-controlled trial. Amyotroph Lateral Scler 1:1-7
14. Jenkins BG, Kilvenyi P, Kustermann E et al (2000) Nonlinear decrease over time in N-acetyl aspartate levels in the absence of neuronal loss and increases in glutamine and glucose in transgenic Huntington's disease mice. J Neurochem 74:2108-2119
15. Rockwood K, Dai D, Mitnitski A (2008) Patterns of decline and evidence of subgroups in patients with Alzheimer's disease taking galantamine for up to 48 months. Int J Geriatr Psychiatry 23:207-214
16. Kempster PA, Williams DR, Selikhova M, Holton J, Revesz T, Lees AJ (2007) Patterns of levodopa response in Parkinson's disease: a clinicopathological study. Brain 130:2123-2128
17. Rosenblatt A, Liang KY, Zhou H et al (2006) The association of CAG repeat length with clinical progression in Huntington disease. Neurology 66:1016-1020
18. Martins CA, Oulhaj A, de Jager CA, Williams JH (2005) ApoE alleles predict the rate of cognitive decline in Alzheimer disease: a nonlinear model. Neurology 65:1888-1893
19. Bracco L, Piccini C, Baccini M et al (2007) Pattern and progression of cognitive decline in Alzheimer's disease: role of premorbid intelligence and ApoE genotype. Dement Geriatr Cogn Disord 24:483-491
20. Kaufman Y, Anaki D, Binns M, Freedman M (2007) Cognitive decline in Alzheimer disease: impact of spirituality, religiosity, and QOL. Neurology 68:1509-1514
21. Small BJ, Backman L (2007) Longitudinal trajectories of cognitive change in preclinical Alzheimer's disease: a growth mixture modeling analysis. Cortex 43:826-834
22. Mitnitski AB, Graham JE, Mogilner AJ, Rockwood K (1999) The rate of decline in function in Alzheimer's disease and other dementias. J Gerontol A Biol Sci Med Sci 54:M65-M69
23. Armon C, Graves MC, Moses D et al (2000) Linear estimates of disease progression predict survival in patients with amyotrophic lateral sclerosis. Muscle Nerve 23:874-882
24. Milliken JK, Edland SD (2000) Mixed effect models of longitudinal Alzheimer's disease data: a cautionary note. Stat Med 19:1617-1629
25. Guimaraes P, Kieburtz K, Goetz CG et al (2005) Non-linearity of Parkinson's disease progression: implication for sample size calculations in clinical trials. Clin Trials 2:509-518
26. Kimura F, Fujimura C, Ishida S, Nakajima H, Furutama D, Uehara H, Shinoda K, Sugino M, Hanafusa T (2006) Progression rate of ALSFRS-R at time of diagnosis predicts survival time in ALS. Neurology 66:265-267
27. Gordon PH, Cheung YK (2006) Progression rate of ALSFRS-R at time of diagnosis predicts survival time in ALS. Neurology 67:1314-1315